A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023

A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea Pasithea Therapeutics Corp., a biotech company looking for new treatments for psychiatric and neurological disorders, [received]( an AU$1 million (US$694,000) grant to help fund research into its new drug candidate for amyotrophic lateral sclerosis (ALS). Australia’s largest independent funder of ALS research FightMND awarded the grant to Pasithea after it added a novel monoclonal antibody (mAb) treatment for the disease to its pipeline as part of its [acquisition]( of Alpha-5 integrin LLC in June. Here’s why the company is exploring the potential of mAbs — and alpha-5/beta-1 integrin blockers in particular — as a potential treatment for ALS. Have Researchers Only Scratched The Surface Of Monoclonal Antibody Treatment Potential? The human body creates antibodies on its own to fight infection. These are proteins in the blood that are each uniquely designed to detect a particular antigen — a kind of “fingerprint” molecule found on pathogens that gives away their identity as foreign invaders. The catch is that the immune system can’t make an antibody for an antigen it’s never seen. That’s where mAbs come in. First developed in 1975, these [lab-made antibodies]( can be engineered to target the specific disease doctors are trying to treat. Once treated, a patient who’s never had something like COVID before will already have those COVID antibodies ready to go. Unlike vaccines that mimic the antigens of a particular pathogen to trigger an immune response so the body will make its own antibodies, mAbs deliver those antibodies ready-made via a direct infusion. Moreover, because they’re engineered in a lab, developers can add extra weapons and features to make them even more powerful. Rituximab, for example, was developed by Biogen Inc. in the 1990s to treat cancer by targeting the CD20 antigen and then delivering cytotoxins that kill the cancer cells as the drug finds them. The Latest Research on ALS Points To Antibody-Based Treatments As A Possible Breakthrough More recently, mAbs have been gaining relevance as a treatment for neurodegenerative diseases, including ALS. ALS is a devastating disease that typically kills patients within [two to five years]( after diagnosis. As motor neurons throughout the brain begin dying at a rapid pace, the brain loses the ability to trigger muscle movements. Eventually, all movements from walking to breathing become impossible. Little is understood about how or why the disease develops or progresses as quickly as it does, which has made finding effective treatments extremely difficult. The reportedly most effective drug on the market is Riluzole, sold under the brand name Rilutek by Sanofi SA . But even with this treatment, patients can only expect to add another [two or three months]( to their prognosis. While the causes are not fully understood, researchers are gaining insights into the actual [processes triggering that destruction]( including oxidative stress, neuroinflammation and protein misfolding. That understanding is what’s spurred the recent interest in [antibody-based therapies for ALS](. The antibody-based therapies currently being investigated for ALS vary in specific targets and mechanisms, but the goal is to stop one or more of those cell destruction processes. Pasithea’s Alpha-5 Integrin Treatment Could Soon Reach Human Trials One of the latest drugs to emerge in this space is Pasithea’s recently acquired drug candidate [PAT103]( a mAb targeting the alpha-5/beta-1 integrin. The alpha-5/beta-1 integrin is a protein on the surface of cells that plays a key role in the brain inflammatory cascade(among other tasks). Researchers have found [high concentrations]( of alpha 5 integrins in areas in the brain where motor neurons are located, both in animal models and human brain samples. Moreover, levels continue to increase as the disease progresses. By blocking this integrin, PAT103 aims to lower their activity and reduce the inflammatory response in the brain. Preclinical research of the anti-alpha-5 integrin treatment has [already yielded promising results](. In animal models of ALS, mice treated with the drug candidate survived longer than controls and experienced improvement in motor function. These studies have been conducted both at Stanford University and in an independent laboratory. Reproducing results is an important step in the scientific process. Based on these data, Pasithea says it plans to run toxicology studies and submit an investigational new drug (IND) application next year, aiming to begin human clinical trials by the end of 2023. This website is wholly owned by tradigital marketing group, inc. (d/b/a “tradigital ir”). Our reports are advertorials and are for general information purposes only. never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our email list, as well as any social networking platforms we may use. please note well: tradigital ir and its employees are not registered investment advisors, broker-dealers, or member(s) of any association for other research providers in any jurisdiction whatsoever. release of liability: through use of this website, viewing or using you agree to hold tradigital ir, its operators, owners, and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. tradigital ir encourages readers and investors to supplement the information in these reports with independent research and other professional advice. all information on featured companies is provided by the companies profiled or is available from public sources and tradigital ir makes no representations, warranties, or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. none of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. instead, tradigital ir strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. tradigital ir’s full disclosure is to be read and fully understood before using tradigital ir's website, or joining tradigital ir's email or text list. From time to time, tradigital ir will disseminate information about a company via website, email, sms, and other points of media. by viewing tradigital ir's website and/or reading tradigital ir's email or text newsletter you are agreeing ----> . all potential percentage gains discussed in any communications are based on calculations from the low to the high of the day. We are engaged in the business of marketing and advertising companies for monetary compensation. in compliance with section 17(b) of the securities act we are disclosing that we have been compensated a fee pursuant to an agreement between tradigital and pasithea therapeutics corp. tradigital was hired for a period beginning january 2022 and ending march 2022 to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We were paid three hundred ninety-four thousand usd via ach. Subsequently, we were paid four hundred ninety-nine thousand usd via ach to publicly disseminate information about pasithea therapeutics corp. via website, email, and sms. We own one hundred fifty thousand restricted common shares of pasithea therapeutics corp., which are eligible for sale on 03/18/2022. For the purpose of this disclaimer, we suggest that you assume we will sell all of our shares once the restriction is lifted on 03/18/2022. Readers are advised to review sec periodic reports: forms 10-q, 10k, form 8-k, insider reports, forms 3, 4, 5 schedule 13d. tradigital ir is compliant with the can-spam act of 2003. tradigital ir does not offer investment advice or analysis, and tradigital ir further urges you to consult your own independent tax, business, financial, and investment advisors. investing in micro-cap, small-cap, and growth securities is highly speculative and carries an extremely high degree of risk. it is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.the private securities litigation reform act of 1995 provides investors a safe harbor in regard to forward-looking statements. any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events, or performance are not statements of historical fact may be forward-looking statements. forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. understand there is no guarantee past performance will be indicative of future results in preparing this publication, tradigital ir has relied upon information supplied by its clients, as well as its clients’ publicly available information and press releases which it believes to be reliable; however, such reliability can not be guaranteed. investors should not rely on the information contained on this website. rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, tradigital ir and its owners, affiliates, subsidiaries, officers, directors, representatives, and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. tradigital ir is not responsible for any claims made by the companies advertised herein, nor is tradigital ir responsible for any other promotional firm, its program, or its structure. tradigital ir is not affiliated with any exchange, electronic quotation system, the securities exchange commission, or finra. No longer want to receive these emails? [Unsubscribe](. TradigitalIR 12 E 49th Street, 11th Fl. New York, NY 10017 ‌